Immucell (ICCC) AI Stock Analysis

• Market Cap: $55.00M
• Dividend Yield: N/A
• Average Volume (3M): 18.70K
• Price to Earnings (P/E): 32.3
• Beta (1Y): -0.27
• Revenue Growth: 21.75%
• EPS Growth: N/A
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 9,045,851
• 10 Day Avg. Volume: 17,725
• 30 Day Avg. Volume: 18,699
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.02
• Enterprise Value/Ebitda: 13.27
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $6.00 ▼(-2.60% Downside)

Immucell's overall stock score is primarily influenced by its mixed financial performance and bearish technical indicators. While there is potential for growth, significant challenges in profitability and weak market momentum weigh heavily on the score. The high P/E ratio further suggests overvaluation, limiting immediate investment appeal.

Immucell Business Overview & Revenue Model

Company Description

Immucell Corporation (ICCC) is a publicly traded biotechnology company focused on developing and commercializing innovative products for the veterinary health market. The company primarily operates in the animal health sector and specializes in creating products that enhance the health and productivity of livestock, particularly dairy and beef cattle. Immucell's core product offerings include its flagship product, First Defense, which is designed to prevent disease in newborn calves by providing them with essential immunoglobulins.

How the Company Makes Money

Immucell generates revenue primarily through the sale of its veterinary products, with a significant focus on First Defense. The company markets its products directly to veterinary clinics and livestock producers, and it benefits from a growing demand for animal health solutions. Its revenue model relies on product sales, which are driven by both direct sales and distribution partnerships. Additionally, Immucell may also engage in strategic partnerships and collaborations that could enhance its product offerings and broaden its market reach, contributing to its overall earnings. The increasing emphasis on animal welfare and the prevention of disease in livestock further bolster Immucell's revenue potential.

Immucell Financial Statement Overview

Summary

ImmuCell shows mixed financial performance with modest revenue growth and improved cash flow. However, profitability remains a concern due to low net margins and negative EBIT margins. The balance sheet is stable with moderate leverage, but the high return on equity may not be sustainable.

Income Statement

The company shows a modest revenue growth rate of 1.2% in the TTM period, indicating some positive momentum. However, the net profit margin is low at 0.18%, and the EBIT margin is negative, reflecting challenges in operational efficiency. The gross profit margin is reasonable at 41.5%, suggesting some ability to manage production costs.

Balance Sheet

The debt-to-equity ratio is moderate at 0.51, indicating a balanced approach to leveraging. The return on equity is notably high at 54.34%, driven by recent profitability, but this may not be sustainable given historical performance. The equity ratio is not explicitly calculated, but the balance sheet shows a reasonable level of equity relative to assets.

Cash Flow

The company has shown significant improvement in free cash flow growth, with a 123.64% increase in the TTM period. The operating cash flow to net income ratio is 0.39, indicating some conversion of earnings to cash. However, the free cash flow to net income ratio is 0.52, suggesting room for improvement in cash generation relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.09B	26.49M	17.47M	18.57M	19.24M	15.34M
Gross Profit	3.36B	7.94M	4.40M	7.65M	8.66M	6.86M
EBITDA	5.36M	1.11M	-2.50M	349.99K	2.72M	1.65M
Net Income	1.76M	-2.16M	-5.77M	-2.49M	-78.00K	-1.02M
Balance Sheet
Total Assets	46.72M	45.10M	43.81M	44.86M	44.47M	40.35M
Cash, Cash Equivalents and Short-Term Investments	6.00M	3.76M	978.74K	5.79M	10.19M	7.95M
Total Debt	14.27M	15.10M	16.69M	12.48M	10.27M	10.73M
Total Liabilities	16.85M	17.58M	18.82M	14.48M	11.89M	12.08M
Stockholders Equity	29.87M	27.52M	24.99M	30.38M	32.58M	28.27M
Cash Flow
Free Cash Flow	1.76M	-107.82K	-6.57M	-5.52M	-1.65M	-2.76M
Operating Cash Flow	2.53M	357.90K	-4.67M	-1.54M	954.17K	1.32M
Investing Cash Flow	-739.61K	-461.23K	-1.89M	-3.96M	-1.60M	-2.57M
Financing Cash Flow	2.88M	2.88M	1.75M	1.11M	3.88M	1.91M

Immucell Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICCC, the sentiment is Negative. The current price of 6.16 is below the 20-day moving average (MA) of 6.39, below the 50-day MA of 6.22, and above the 200-day MA of 5.84, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.98 is Neutral, neither overbought nor oversold. The STOCH value of 20.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ICCC.

Immucell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARTV	53 Neutral	$146.80M	―	-86.18%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ICCC	49 Neutral	$55.00M	32.27	6.61%	―	21.75%	―
HOWL	46 Neutral	$74.08M	―	-100.55%	―	-100.00%	-22.09%
ACET	27 Underperform	$136.40M	-0.68	-64.39%	―	―	48.45%

Immucell Corporate Events

Immucell Appoints New CEO Olivier te Boekhorst

ImmuCell Corporation announced on September 29, 2025, the appointment of Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Mr. te Boekhorst brings extensive experience from his previous roles at ARCHIMED and IDEXX Laboratories, where he led significant growth and innovation in the livestock diagnostics sector. This leadership change is expected to drive the company’s growth, particularly in expanding sales of First Defense® and advancing Re-Tain®. The transition will be supported by the current CEO, Michael F. Brigham, who will remain as a Special Advisor and Board member. The company has also structured stock option awards for Mr. te Boekhorst as part of his employment terms.

The most recent analyst rating on (ICCC) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Immucell stock, see the ICCC Stock Forecast page.

ImmuCell’s Earnings Call: Strong Growth Amid Challenges

ImmuCell’s recent earnings call painted a picture of strong financial performance, marked by significant sales growth and improved gross margins. The company successfully refinanced its debt, which bodes well for its financial stability. However, the call also highlighted some challenges, including potential sales softening, delays in FDA approval for Re-Tain, and the need to rebuild customer trust after previous supply issues.

ImmuCell Extends $1M Credit Line with Bank

On August 20, 2025, ImmuCell Corporation extended its $1 million line of credit with Maine Community Bank through September 11, 2026, with interest at the National Prime Rate. This extension provides ImmuCell with continued financial flexibility, potentially impacting its operational capabilities and market positioning positively.

The most recent analyst rating on (ICCC) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Immucell stock, see the ICCC Stock Forecast page.

ImmuCell Reports Strong Sales Growth and Profitability

ImmuCell Corporation is a growing animal health company that focuses on developing, manufacturing, and marketing scientifically proven products to enhance the health and productivity of dairy and beef cattle.

ImmuCell Refinances Debt with Maine Community Bank

On August 7, 2025, ImmuCell Corporation entered into a loan agreement with Maine Community Bank to refinance a portion of its bank debt. The new loan, amounting to $2,327,119 with a fixed interest rate of 6.5%, was used to pay off existing loans from MCB and the Finance Authority of Maine, which had higher interest rates and balloon payments due in 2026. This refinancing is expected to improve ImmuCell’s financial stability and reflects its ongoing productive relationship with MCB and support from FAME.